Natural resources exploitation: business and human rights (Editor)

Published: 15 November 2018

Can natural resources exploitation continue as a no-limit business? If measures have to be taken, what are they? Are compromises possible or should certain activities simply be stopped or dramatically reduced, with the economic consequences that we can imagine, including for employees?

Distinguished speakers of diverse backgrounds examined these issues during the Main Theme Session on “Natural Resources Exploitation: Business and Human Rights”, held on 28 October 2017 during the UIA’s 61st Congress in Toronto.

This fourth book in the UIA-LexisNexis Publications Collection contains the speakers’ written contributions to the Congress, as well as contributions of other experts in the field, and examines the legal issues arising from the exploitation of natural resources on a legislative, administrative and contractual level, in addition to focusing on compliance mechanisms, dispute resolution and other mechanisms for redress.

Related publications

SEE ALL

Insights

Insights – 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights – 23.04.2026

Swiss Federal Supreme Court holds Swiss Russia sanctions are overriding mandatory law and can bar enforcement of arbitral awards

Swiss Federal Supreme Court holds Swiss Russia sanctions are overriding…

<p>In decision 4A_305/2025 of 13 March 2026, the Swiss Federal Supreme Court held that Swiss sanctions against Russia are overriding mandatory law and apply irrespective of the otherwise applicable law. The Court reasoned that the Swiss Ukraine Ordinance serves Switzerland’s core foreign-policy objectives and therefore applies as overriding mandatory law. In this case, the Court held that the sanctions barred enforcement of the award in Switzerland and treated the claim as unenforceable while the sanctions remain in force.</p>
SEE ALL
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}